These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8254500)

  • 1. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
    Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
    J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
    Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
    Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
    Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
    Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal MTP-PE.
    Gano JB; Kleinerman ES
    J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
    [No Abstract]   [Full Text] [Related]  

  • 6. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse.
    Fedorocko P
    Int J Radiat Biol; 1994 Apr; 65(4):465-75. PubMed ID: 7908934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.
    Venkatakrishnan K; Kramer WG; Synold TW; Goodman DB; Sides E; Oliva C
    Eur J Clin Pharmacol; 2012 Oct; 68(10):1347-55. PubMed ID: 22460239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
    Fogler WE; Wade R; Brundish DE; Fidler IJ
    J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
    Meyers PA; Chou AJ
    Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
    Verweij J; Judson I; Steward W; Coleman R; Woll P; van Pottelsberghe C; van Glabbeke M; Mouridsen H
    Eur J Cancer; 1994; 30A(6):842-3. PubMed ID: 7917546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M; Knowles RD; Kleinerman ES
    Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.
    Dinney CP; Tanguay S; Bucana CD; Eve BY; Fidler IJ
    J Interferon Cytokine Res; 1995 Jun; 15(6):585-92. PubMed ID: 7553228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
    Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU
    J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
    Anderson P
    Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
    Mori K; Ando K; Heymann D
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal MTP-PE: a promising new biologic response modifier.
    Gano JB; Kleinerman ES
    Oncol Nurs Forum; 1995 Jun; 22(5):809-16. PubMed ID: 7675688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
    MacEwen EG; Kurzman ID; Rosenthal RC; Smith BW; Manley PA; Roush JK; Howard PE
    J Natl Cancer Inst; 1989 Jun; 81(12):935-8. PubMed ID: 2733037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
    Maeda M; Asano T; Kleinerman ES
    Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.